28.07.2010 • NewsChinacooperationMerck & Co.

Merck & Co Ties with Sinopharm to Boost China Presence

Merck & Co said on Tuesday it struck a deal with Sinopharm Group to market the U.S. drugmaker's cervical cancer vaccine and other vaccines in China, as the pharmaceutical industry seeks greater inroads in Asia.

The alliance, for which terms were not announced, is the first such deal Merck has struck to expand its China presence and includes the potential for marketing other Merck products.

Like rivals, Merck has made increasing its sales in emerging markets a cornerstone of its growth strategy. It has projected that more than 25% of its pharmaceutical and vaccine sales will come from emerging markets by 2013, up from 17% currently.

Merck told investors in May it already had a 3,000-strong sales force in China, an increase of 90% since 2007.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.